The UK and US have concluded a major commercial pact that will preserve zero tariffs on British pharmaceutical products entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has agreed to raise funding on drugs through the public health system. This commitment secures that tariffs on these key products will be held at zero for a duration of the next three years.
This agreement is in response to recent statements to dramatically increase tariffs on patented drug imports, with increases mentioned reaching double the cost.
"This agreement between the Britain bolsters the international landscape for new treatments and establishes long-overdue fairness to American-British drug exports," an announcement declared.
Trade Impact
Medicines constitute one of the UK's biggest export categories to the United States, which is clearly the biggest market for leading British pharmaceutical firms.
Statistics show that in the one-year period to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This deal safeguards work, boosts capital expenditure and sets the stage for the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary commented.
Detailed British Pledges
The agreement involves several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new therapies to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to raise overall health service expenditure on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, refunds topped 20%.
Recent Tensions
This agreement comes amid a ongoing dispute between the drug companies and the ministers over medicine costs and NHS adoption.
The disagreement were heightened by claims that American consumers were paying significantly more for the equivalent treatments than people in the other developed nations.
In recent months, several large manufacturing plans in the UK have been delayed or abandoned, while multi-billion-dollar investments have been directed toward American operations.
The Science Minister publicly accepted that the NHS needed to increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a proportion of its resources over the last ten years.
